hydroxyethyl starch in sodium chloride
Voluven	Pharmaceutical company: Fresenius Kabi www.fresenius-kabi.com

Pharmacologic classification: colloid
Therapeutic classification: plasma expander
Pregnancy risk category: C

AVAILABLE FORMS
Plastic I.V. solution container: 500 ml

INDICATIONS AND DOSAGES
Treatment and prevention of hypovolemia--
Adults: Start I.V. infusion slowly to monitor for anaphylactic reactions. Base daily dose and rate on patient’s blood loss, hemodynamics, and hemodilution effects; up to 50 ml/kg/day (3500 ml for a 70-kg patient).
Children: Start I.V. infusion slowly to monitor for anaphylactic reactions. Give 7 to 25 mg/kg/day based on patient’s blood loss, hemodynamics, and hemodilution effects.
ADJUST-A-DOSE:
For geriatric or renally impaired patients, the risk of adverse reactions is greater. Monitor closely and adjust dosage accordingly.

CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients hypersensitive to hydroxyethyl starch, in those receiving dialysis, and in those with fluid overload, pulmonary edema, heart failure, severe hypernatremia, severe hyperchloremia, intracranial bleeding, or renal failure with oliguria or anuria.
   Contraindicated as initial treatment of dehydration; a crystalloid solution should be given first.
   Use cautiously in pregnant and breast-feeding patients.

INTERACTIONS
None reported.

ADVERSE REACTIONS
CV: hypervolemia (heart failure, pulmonary edema, hypertension).
Hematologic: anemia, coagulopathy, elevated serum amylase.
Other: hypersensitivity reactions, pruritus.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our Disclaimer .

© Copyright 2008 by Lippincott Williams & Wilkins